These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21737488)

  • 21. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
    Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
    Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells.
    Caccamo AE; Desenzani S; Belloni L; Borghetti AF; Bettuzzi S
    J Cell Physiol; 2006 Apr; 207(1):208-19. PubMed ID: 16331665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heat shock protein inhibitors increase the efficacy of measles virotherapy.
    Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E
    Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer.
    Ma L; Sato F; Sato R; Matsubara T; Hirai K; Yamasaki M; Shin T; Shimada T; Nomura T; Mori K; Sumino Y; Mimata H
    Oncol Rep; 2014 Jun; 31(6):2482-92. PubMed ID: 24718854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hsp90 inhibitors in breast cancer: a systematic review.
    Zagouri F; Sergentanis TN; Chrysikos D; Papadimitriou CA; Dimopoulos MA; Psaltopoulou T
    Breast; 2013 Oct; 22(5):569-78. PubMed ID: 23870456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
    Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
    Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.
    Cao C; Shinohara ET; Li H; Niermann KJ; Kim KW; Sekhar KR; Gleave M; Freeman M; Lu B
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1228-36. PubMed ID: 16253777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
    Roh JL; Kim EH; Park HB; Park JY
    Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
    Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.